Drug Patents owned by Salix

1. Drug name - FENOGLIDE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8124125 SALIX Solid dosage form comprising a fibrate Oct, 2024

(1 year, 11 months from now)

US9173847 SALIX Tablet comprising a fibrate Oct, 2024

(1 year, 11 months from now)

US8481078 SALIX Solid dosage form comprising a fibrate Oct, 2024

(1 year, 11 months from now)

US7658944 SALIX Solid dosage form comprising a fibrate Dec, 2024

(2 years from now)

Drugs and Companies using FENOFIBRATE ingredient

Treatment: For reducing total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides, and treating hypertriglyceridemia; Use of fenofibrate for reducing elevated total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
40MG TABLET;ORAL Prescription
120MG TABLET;ORAL Prescription

2. Drug name - PLENVU

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10792306 SALIX Colonoscopy—preparation Mar, 2032

(9 years from now)

US10780112 SALIX Colonoscopy-preparation Mar, 2032

(9 years from now)

US10646512 SALIX Colonoscopy - preparation Mar, 2032

(9 years from now)

US9592252 SALIX Colonoscopy—preparation Aug, 2032

(9 years from now)

US10918723 SALIX Colon cleansing compositions and methods of use Sep, 2033

(10 years from now)

US8999313 SALIX Compositions Sep, 2033

(10 years from now)

US9707297 SALIX Compositions Sep, 2033

(10 years from now)

US9326969 SALIX Compositions Sep, 2033

(10 years from now)

US10016504 SALIX Compositions Sep, 2033

(10 years from now)

Drugs and Companies using ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE ingredient

Treatment: For cleansing of the colon in preparation for colonoscopy in adults

Dosage: FOR SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
7.54GM;140GM;2.2GM;48.11GM;5.2GM;9GM FOR SOLUTION;ORAL Prescription

3. Drug name - RELISTOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9180125 SALIX Peripheral opioid receptor antagonists and uses thereof Sep, 2029

(6 years from now)

US9492445 SALIX Peripheral opioid receptor antagonists and uses thereof Sep, 2029

(6 years from now)

US9724343 SALIX Peripheral opioid receptor antagonists and uses thereof Sep, 2029

(6 years from now)

US8420663 SALIX Peripheral opioid receptor antagonists and uses thereof Sep, 2029

(6 years from now)

US8956651 SALIX Oral formulations and lipophilic salts of methylnal trexone Mar, 2031

(8 years from now)

US8524276 SALIX Oral formulations and lipophilic salts of methylnaltrexone Mar, 2031

(8 years from now)

US10307417 SALIX Oral formulations and lipophilic salts of methylnaltrexone Mar, 2031

(8 years from now)

US9314461 SALIX Oral formulations and lipophilic salts of methylnaltrexone Mar, 2031

(8 years from now)

US10376505 SALIX Oral formulations and lipophilic salts of methylnaltrexone Mar, 2031

(8 years from now)

Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient

Treatment: Treatment of opioid-induced constipation

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
150MG TABLET;ORAL Prescription

4. Drug name - TRULANCE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7799897 SALIX Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
Jun, 2022

(3 months ago)

US7041786 SALIX Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
Jan, 2028

(5 years from now)

US10011637 SALIX Ultra-pure agonists of guanylate cyclase C, method of making and using same
Jun, 2034

(11 years from now)

CN103641892B SALIX Guanylate Cyclase Receptor Agonist For Treating Tissue Inflammation And Cancer
Mar, 2022

(6 months ago)

CN102643333B SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

CN102643333A SALIX Guanylate Cyclase Receptor Stimulant For Treating Tissue Inflammation And Canceration
Mar, 2022

(6 months ago)

CN103641892A SALIX For Treating Tissue Inflammation And Cancer Of Guanylate Cyclase Receptor Agonist
Mar, 2022

(6 months ago)

CN105764916B SALIX A Hyperpure Agonist Of Guanylate Cyclase C, Preparation And Use Method Of The Agonist
Jun, 2034

(11 years from now)

CN105764916A SALIX A Super-Pure Agonist Of Guanylate Cyclase C, Preparation And Using Method Of The Agonist
Jun, 2034

(11 years from now)

EP2103624B1 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

EP2301952A2 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

EP2944648B1 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Organ Inflammation
Mar, 2022

(6 months ago)

EP2301952B1 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

EP2103624A1 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

EP2944648A1 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Organ Inflammation
Mar, 2022

(6 months ago)

EP2301952A3 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

EP1379224B1 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

EP1379224A4 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

EP1379224A1 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

EP1379224B2 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9919024 SALIX Formulations of guanylate cyclase C agonists and methods of use Sep, 2031

(8 years from now)

US9925231 SALIX Formulations of guanylate cyclase C agonists and methods of use Sep, 2031

(8 years from now)

US9610321 SALIX Formulations of guanylate cyclase C agonists and methods of use Sep, 2031

(8 years from now)

US9616097 SALIX Formulations of guanylate cyclase C agonists and methods of use Aug, 2032

(9 years from now)

US11142549 SALIX Ultra-pure agonists of guanylate cyclase C, method of making and using same Jun, 2034

(11 years from now)

Drugs and Companies using PLECANATIDE ingredient

Treatment: Irritable bowel syndrome with constipation; chronic idiopathic constipation; Chronic idiopathic constipation; irritable bowel syndrome with constipation

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
3MG TABLET;ORAL Prescription

5. Drug name - UCERIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895064 SALIX Controlled release and taste masking oral pharmaceutical composition Sep, 2031

(8 years from now)

US9132093 SALIX Controlled release and taste making oral pharmaceutical composition Sep, 2031

(8 years from now)

US10307375 SALIX Controlled release and taste masking oral pharmaceutical composition Sep, 2031

(8 years from now)

US9192581 SALIX Controlled release and taste masking oral pharmaceutical composition Sep, 2031

(8 years from now)

US10660858 SALIX Controlled release and taste masking oral pharmaceutical composition Sep, 2031

(8 years from now)

Drugs and Companies using BUDESONIDE ingredient

Treatment: Induction of remission in patients with active, mild to moderate ulcerative colitis

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
9MG TABLET, EXTENDED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.